Menu Close

BlackDiamond Wealth Management Inc. Acquires 175 Shares of Johnson & Johnson (NYSE:JNJ)

view original post

BlackDiamond Wealth Management Inc. grew its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 2.3% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 7,791 shares of the company’s stock after acquiring an additional 175 shares during the quarter. Johnson & Johnson comprises about 1.6% of BlackDiamond Wealth Management Inc.’s portfolio, making the stock its 21st biggest holding. BlackDiamond Wealth Management Inc.’s holdings in Johnson & Johnson were worth $1,381,000 as of its most recent filing with the SEC.

Other institutional investors have also recently modified their holdings of the company. Riversedge Advisors LLC lifted its position in shares of Johnson & Johnson by 8.6% during the 4th quarter. Riversedge Advisors LLC now owns 3,664 shares of the company’s stock worth $627,000 after buying an additional 289 shares during the last quarter. Insight Wealth Strategies LLC raised its position in Johnson & Johnson by 22.0% in the fourth quarter. Insight Wealth Strategies LLC now owns 13,713 shares of the company’s stock valued at $2,346,000 after purchasing an additional 2,473 shares during the last quarter. Northstar Group Inc. raised its position in Johnson & Johnson by 2.3% in the fourth quarter. Northstar Group Inc. now owns 45,522 shares of the company’s stock valued at $7,788,000 after purchasing an additional 1,004 shares during the last quarter. Ieq Capital LLC raised its position in Johnson & Johnson by 3.6% in the fourth quarter. Ieq Capital LLC now owns 108,946 shares of the company’s stock valued at $18,637,000 after purchasing an additional 3,814 shares during the last quarter. Finally, Raymond James Trust N.A. raised its position in Johnson & Johnson by 1.3% in the fourth quarter. Raymond James Trust N.A. now owns 173,776 shares of the company’s stock valued at $29,728,000 after purchasing an additional 2,281 shares during the last quarter. 68.78% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on JNJ. Morgan Stanley increased their target price on Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a research report on Friday, July 8th. SVB Leerink decreased their price target on Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. Wells Fargo & Company increased their price target on Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research note on Wednesday, July 13th. Finally, Raymond James increased their price target on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $189.89.

Johnson & Johnson Trading Down 0.4 %

NYSE JNJ opened at $171.11 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.42 and a quick ratio of 1.14. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The business has a 50 day simple moving average of $175.21 and a 200 day simple moving average of $174.55. The stock has a market capitalization of $449.88 billion, a P/E ratio of 24.91, a P/E/G ratio of 3.32 and a beta of 0.59.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The firm had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. During the same quarter last year, the firm posted $2.48 earnings per share. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. Research analysts expect that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be issued a dividend of $1.13 per share. The ex-dividend date is Monday, August 22nd. This represents a $4.52 annualized dividend and a yield of 2.64%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 65.79%.

Insider Activity at Johnson & Johnson

In other news, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares in the company, valued at approximately $2,785,140. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.